SCHEMBL7743334

SCHEMBL7743334

Brc1ccccc1-c1nc2ccccc2o1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.67
TP53 P04637 6/20 0.67
SMN1; SMN2 Q16637 5/20 0.67
KMT2A Q03164 5/20 0.61
C1R P00736 1/20 0.61
NPC1 O15118 7/20 0.55
RAB9A P51151 7/20 0.55
HPGD P15428 6/20 0.55
ALDH1A1 P00352 6/20 0.55
HSD17B10 Q99714 6/20 0.55
KDM4E B2RXH2 5/20 0.55
NFKB1 P19838 2/20 0.55
NFKB2 Q00653 2/20 0.55
RELA Q04206 2/20 0.55
TOP2A P11388 1/20 0.54
ELANE P08246 1/20 0.54
PKM P14618 2/20 0.53
GLA P06280 1/20 0.53
GAA P10253 1/20 0.53
CASP1 P29466 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29404641 1.00 MAPT (0.67) MAPTTP53SMN1; SMN2KMT2AC1R
SCHEMBL1832604 0.86 NPC1 (0.61) MAPTTP53SMN1; SMN2KMT2ANPC1
SCHEMBL171055 0.86 TOP2A (0.62) MAPTTP53SMN1; SMN2KMT2ANPC1
SCHEMBL29504749 0.86 TOP2A (0.62) MAPTTP53SMN1; SMN2KMT2ANPC1
SCHEMBL15976158 0.85 TOP2A (0.58) MAPTTP53SMN1; SMN2KMT2ANPC1
SCHEMBL10852717 0.85 MAPT (0.52) MAPTTP53SMN1; SMN2KMT2AC1R
SCHEMBL12854009 0.84 TOP2A (0.60) MAPTTP53SMN1; SMN2KMT2ANPC1
SCHEMBL10415479 0.83 MAPT (0.62) MAPTTP53SMN1; SMN2KMT2AC1R
SCHEMBL824375 0.82 NPC1 (0.69) MAPTTP53SMN1; SMN2KMT2ANPC1
SCHEMBL29531707 0.82 NPC1 (0.69) MAPTTP53SMN1; SMN2KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113135923-B Composition for cover layer of organic electroluminescent device and organic electroluminescent device comprising same 伊爱尔安株式会社 2023-09-12 CN disclosed
CN-114105998-A Composition for capping layer of organic electroluminescent device and organic electroluminescent device comprising same 伊爱尔安株式会社 2022-03-01 CN disclosed
CN-108602812-B Bicyclic hydroxamic acids useful as inhibitors of histone deacetylase activity in mammals 坎塞拉有限公司 2021-11-02 CN disclosed
EP-3394052-B1 BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY KANCERA AB (SE) 2021-07-28 EP disclosed
CN-113135923-A Composition for capping layer of organic electroluminescent device and organic electroluminescent device comprising same 伊爱尔安株式会社 2021-07-20 CN disclosed
US-10654814-B2 Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity KANCERA AB (SE) 2020-05-19 US disclosed
US-20190284147-A1 BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY KANCERA AB (SE) 2019-09-19 US disclosed
CN-109457268-A A kind of method of electro-catalysis benzamide compound synthesis benzoxazoles 福建医科大学 2019-03-12 CN disclosed
CN-109369555-A A kind of method of microwave radiation benzamide compound synthesis benzoxazoles in water phase 福建医科大学 2019-02-22 CN disclosed
CN-109265409-A A kind of synthetic method of the benzoxazoles that 2- replaces and benzothiazole and its derivative that 2- replaces 重庆医科大学 2019-01-25 CN disclosed
CN-109180590-A A method of Benzoheterocyclic compounds are quickly prepared using physical grinding method under room temperature solvent-free 福建医科大学 2019-01-11 CN disclosed
EP-3394052-A1 BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY Kancera AB (SE) 2018-10-31 EP disclosed
WO-2017108282-A1 BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY KANCERA AB (SE) 2017-06-29 WO disclosed
US-8697872-B2 Boron compounds and uses thereof QUEEN'S UNIVERSITY AT KINGSTON (CA) 2014-04-15 US disclosed
US-20120253044-A1 Boron Compounds and Uses Thereof WANG, SUNING (CA) 2012-10-04 US disclosed
EP-1039915-A4 CYCLIC PHOSPHONATE ESTER INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD BRISTOL MYERS SQUIBB CO (US) 2001-02-14 EP disclosed
EP-1039915-A1 CYCLIC PHOSPHONATE ESTER INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD BRISTOL-MYERS SQUIBB COMPANY (US) 2000-10-04 EP disclosed
WO-1999021564-A1 CYCLIC PHOSPHONATE ESTER INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD BRISTOL-MYERS SQUIBB COMPANY (US) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10654814-B2 Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity HDAC1, HDAC11, HDAC10 MAPT 1282/4885TP53 1424/4885SMN1; SMN2 983/4885
US-20190284147-A1 BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY HDAC1, HDAC11, HDAC10 MAPT 1282/4885TP53 1424/4885SMN1; SMN2 983/4885
US-20120253044-A1 Boron Compounds and Uses Thereof BRI3BP, BRSK1, BROX MAPT 1597/4885TP53 2830/4885SMN1; SMN2 1497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.